Recurrence Patterns and Overtreatment in Pure DCIS: A Retrospective Clinical and Radiological Follow-Up Study
Authors:
- Maria Concetta TorrioneMTMaria Concetta Torrione
- Andrea Gaia AzzaritoAAAndrea Gaia Azzarito
- Vanessa MarisiVMVanessa Marisi
- Maria Francesca SavinaMSMaria Francesca Savina
- Angela Di CredicoACAngela Di Credico
- Riccardo LubertiRLRiccardo Luberti
- Marzia MuziMMMarzia Muzi
- Claudia D'EramoCDClaudia D'Eramo
- Massimo CauloMCMassimo Caulo
- Andrea Delli PizziAPAndrea Delli Pizzi
Open Access
- 25 May 2026
- journal article
- research article
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 16 (6) , 281
Abstract
Background/Objectives: The clinical management of ductal carcinoma in situ (DCIS) remains controversial due to its heterogeneous biological behavior and uncertain risk of progression. Standard treatment often includes surgery and radiotherapy, although the actual recurrence risk varies considerably among patients. This study aimed to evaluate recurrence patterns and associated clinicopathological factors in a large single-center cohort of patients with pure DCIS. Methods: We retrospectively analyzed 403 patients with histologically confirmed pure DCIS treated with breast-conserving surgery or mastectomy between 2016 and 2023. Clinical, imaging, pathological, and treatment-related variables were assessed. Descriptive and exploratory comparative analyses were performed between patients with and without ipsilateral recurrence. Results: A total of 417 lesions were analyzed, with 21 ipsilateral recurrences (5%) observed during follow-up. Among recurrent cases, 57% were non-invasive recurrent DCIS and 38% were invasive carcinomas. Most recurrences occurred in patients treated with breast-conserving surgery, and 52% of recurrent patients had not received adjuvant radiotherapy. All recurrent cases were estrogen receptor–positive at initial diagnosis, whereas none had received endocrine therapy. No clear association between recurrence patterns and tumor grade or tumor size emerged in this exploratory analysis. No distant metastases or disease-related deaths were observed during follow-up. Conclusions: Recurrence after treatment for pure DCIS was relatively uncommon and frequently non-invasive. Traditional clinicopathological variables alone appeared insufficient to consistently identify recurrence patterns in this cohort. These findings support the need for more individualized risk stratification approaches integrating clinical, imaging, and molecular factors in order to reduce potential overtreatment in selected patients with DCIS.Keywords
This publication has 30 references indexed in Scilit:
- Active Monitoring With or Without Endocrine Therapy for Low-Risk Ductal Carcinoma In SituJAMA, 2025
- Outcomes from low-risk ductal carcinoma in situ: a systematic review and meta-analysisBreast Cancer Research and Treatment, 2024
- Role of contrast-enhanced mammography in the preoperative detection of ductal carcinoma in situ of the breasts: a comparison with low-energy image and magnetic resonance imagingEuropean Radiology, 2023
- Ductal carcinoma in situ of breast: update 2019Pathology, 2019
- Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trialThe Lancet, 2016
- Addressing overtreatment of screen detected DCIS; the LORIS trialEuropean Journal of Cancer, 2015
- Rethinking the Standard for Ductal Carcinoma In Situ TreatmentJAMA Oncology, 2015
- Breast Cancer Mortality After a Diagnosis of Ductal Carcinoma In SituJAMA Oncology, 2015
- Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ – The LORD studyEuropean Journal of Cancer, 2015
- Survival Benefit of Breast Surgery for Low-Grade Ductal Carcinoma In SituJAMA Surgery, 2015